Table 2 Results of the study for all participants
| Â | N | % (95% CI) |
|---|---|---|
Total maternal recruits | 103 | Â |
 Withdrawals | 2 |  |
 Stillbirths | 3 |  |
 Neonatal deaths | 2 |  |
Total infants screened + followed up* | 99 | Â |
Any evidence of infection | 55 | 55.6 (45.2:65.5) |
 Positive screen | ||
  Day 1 | 8 | 8.1 (3.6:15.3) |
  Interim | 27 | 27.3 (18.8:37.1) |
  Day 90 | 3 | 3.0 (0.6:8.6) |
  Day 1 and/or interim and/or day 90 | 30 | 30.3 (21.5:40.4) |
Clinical diagnosis of infection (from clinical notes) | 19 | 19.2 (12.0:28.3) |
 Oomphalitis | 1 | 1.0 (< 0.1:5.5) |
 Pneumonia | 2 | 2.0 (0.2:7.1) |
 Diarrhoea | 1 | 1.0 (< 0.1:5.5) |
 Neonatal septicaemia | 6 | 6.1 (2.3:12.7) |
 Upper respiratory tract infection | 3 | 3.0 (0.6:8.6) |
 Skin pustules/infection | 3 | 3.0 (0.6:8.6) |
Evidence from all three sources | 12 | 12.1 (6.4:20.2) |
 Unspecified source | 3 | 3.0 (0.6:8.6) |
 Microbiological evidence | 5 | 5.1 (1.7:11.4) |
 Maternally reported infection | 45 | 45.5 (35.4:55.8) |
 Received antibiotics | 22 | 22.2 (14.5:31.7) |
 Infants receiving antimalarial medication | 8 | 8.1 (3.6:15.3) |